流感疫苗接种与缺血性卒中风险:一项基于人群的病例对照研究
在西班牙初级保健数据库2001-2015年开展巢式病例对照研究,纳入3757621人的源队列,选取14322例首发缺血性卒中病例和71610名匹配对照。流感疫苗接种与缺血性卒中的aOR为0.88(95%CI 0.84-0.92),早期显现并随时间略减;肺炎球菌疫苗接种未见风险降低(aOR 1.08;95%CI 1.04-1.13)。
要点
- 流感疫苗接种与缺血性卒中风险降低相关(aOR 0.88;95%CI 0.84-0.92)。
- 保护效应早期出现(15-30天aOR 0.79;95%CI 0.69-0.92),随时间略减。
- 肺炎球菌疫苗接种未显示与缺血性卒中风险降低相关(aOR 1.08;95%CI 1.04-1.13)。
核心结论
- 结果与流感疫苗对缺血性卒中具有中等保护作用的结论相符,该保护作用在接种后早期出现。
- 流行前时期也观察到风险降低,提示保护作用可能不完全与预防流感感染有关,或部分可由未测量的混杂因素解释。
研究设计与样本
- 在西班牙初级保健数据库2001-2015年开展的巢式病例对照研究。
- 源队列为年龄40-99岁、注册至少1年且无卒中或癌症病史者,共3757621人。
- 识别首发缺血性卒中病例并分类为心源性栓塞型和非心源性栓塞型,每例随机选取5名对照,按年龄、性别和卒中诊断日期(索引日期)个体匹配。
- 疫苗接种定义为同一季节内索引日期前至少14天有流感疫苗接种记录。
- 采用条件logistic回归计算调整比值比(aOR)及95%CI,并以肺炎球菌疫苗接种作为阴性对照。
主要发现
- 共纳入14322例首发缺血性卒中病例(非心源性栓塞型9542例,心源性栓塞型4780例)和71610名匹配对照,疫苗接种率分别为41.4%和40.5%,粗OR为1.05(95%CI 1.01-1.10)。
- 接种疫苗的患者血管危险因素、疾病和合并用药的患病率高于未接种者;完全调整后,流感疫苗接种与缺血性卒中的aOR为0.88(95%CI 0.84-0.92)。
- 保护作用早期出现(15-30天aOR 0.79;95%CI 0.69-0.92),并随时间略减(>150天aOR 0.92;95%CI 0.87-0.98)。
- 两种类型缺血性卒中、3个流行期以及所有亚组(男性、女性、65岁以下和65岁及以上个体、中危和高危血管风险者)中均观察到相似幅度的风险降低。
- 肺炎球菌疫苗接种与缺血性卒中风险降低无关(aOR 1.08;95%CI 1.04-1.13)。
局限性
- 流行前时期也观察到风险降低,提示保护作用可能不完全与预防流感感染有关,或部分可由未测量的混杂因素解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To assess the relationship between influenza vaccination in the general population and risk of a first ischemic stroke (IS) during pre-epidemic, epidemic, and postepidemic periods. METHODS: A nested case-control study was conducted in a Spanish primary care database over 2001-2015. Individuals aged 40-99 years with at least 1 year registry and no history of stroke or cancer were selected to conform the source cohort, from which incident IS cases were identified and classified as cardioembolic or noncardioembolic. Five controls per case were randomly selected, individually matched with cases for exact age, sex, and date of stroke diagnosis (index date). A patient was considered vaccinated when he/she had a recorded influenza vaccination at least 14 days before the index date within the same season. Adjusted odds ratios (aORs) and their respective 95% CIs were computed through a conditional logistic regression. Pneumococcal vaccination was used as a negative control. RESULTS: From a cohort of 3,757,621 patients, we selected 14,322 incident IS cases (9,542 noncardioembolic and 4,780 cardioembolic) and 71,610 matched controls. Of them, 41.4% and 40.5%, respectively, were vaccinated yielding a crude OR of 1.05 (95% CI 1.01-1.10). Vaccinated patients presented a higher prevalence of vascular risk factors, diseases, and comedication than those nonvaccinated, and after full adjustment, the association of influenza vaccination with IS yielded an aOR of 0.88 (95% CI 0.84-0.92), appearing early (aOR15-30 days 0.79; 95% CI 0.69-0.92) and slightly declining over time (aOR>150 days 0.92; 95% CI 0.87-0.98). A reduced risk of similar magnitude was observed with both types of IS, in the 3 epidemic periods, and in all subgroups analyzed (men, women, individuals younger and older than 65 years of age, and those with intermediate and high vascular risk). By contrast, pneumococcal vaccination was not associated with a reduced risk of IS (aOR 1.08; 95% CI 1.04-1.13). DISCUSSION: Results are compatible with a moderate protective effect of influenza vaccine on IS appearing early after vaccination. The finding that a reduced risk was also observed in pre-epidemic periods suggests that either the "protection" is not totally linked to prevention of influenza infection or it may be partly explained by unmeasured confounding factors.
引用
- Rodríguez-Martín S, Barreira-Hernández D, Gil M, et al. Influenza Vaccination and Risk of Ischemic Stroke: A Population-Based Case-Control Study. Neurology. 2022. PMID: 36240087. doi:10.1212/WNL.0000000000201123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。